Search

Your search keyword '"Prowell, TM"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Prowell, TM" Remove constraint Author: "Prowell, TM"
30 results on '"Prowell, TM"'

Search Results

2. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

3. Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis

4. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

7. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.

9. The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage.

10. U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.

11. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.

12. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.

13. Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

14. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.

15. Words Matter: Use of Respectful Language in Oncology.

17. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.

18. Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.

20. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

21. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

22. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

23. Seamless Oncology-Drug Development.

24. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.

26. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.

27. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.

28. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?

30. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?

Catalog

Books, media, physical & digital resources